Amyotrophic Lateral Sclerosis (ALS) News and Research

RSS

Proteostasis acquires Harvard University's two novel protein target licenses

Proteostasis Therapeutics announced today that it has acquired two exclusive licenses from Harvard University to technologies for enhancing the activity of a key cellular protein clearance mechanism, the ubiquitin-proteasome pathway.

27 Apr 2011

Major breakthrough in understanding of amyotrophic lateral sclerosis

Brandeis researchers have made a significant advance in the effort to understand amyotrophic lateral sclerosis by successfully reversing the toxicity of the mutated protein in the familial type of the disease.

27 Apr 2011

Rxi secures SBIR grants to develop novel RNAi therapeutics for ALS

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted and immunotherapy technologies, today announced that it was awarded two Small Business Innovation Research grants from the National Institutes of Health.

27 Apr 2011

Researchers report game-changing advance in stem cell science

In a paper published in the April 25 early online edition of the Proceedings of the National Academy of Sciences, researchers at the University of California, San Diego School of Medicine, the Gladstone Institutes in San Francisco and colleagues report a game-changing advance in stem cell science: the creation of long-term, self-renewing, primitive neural precursor cells from human embryonic stem cells that can be directed to become many types of neuron without increased risk of tumor formation.

26 Apr 2011

U-M receives Taubman Institute's $100 million gift for innovative medical science

A. Alfred Taubman has become U-M's largest individual donor, with total giving of more than $142 million. His latest gift of $56 million to the A. Alfred Taubman Medical Research Institute, announced today before the University's Board of Regents, will bring his support of innovative medical science at the University of Michigan to a total of $100 million.

25 Apr 2011

Biogen Idec first quarter revenues increase 9% to $1.2 billion

Biogen Idec Inc., a global biotechnology leader in the discovery, development, manufacturing and commercialization of innovative therapies, today announced its first quarter 2011 results.

21 Apr 2011

Neuralstem signs MoU with BaYi Brain Hospital for ischemic stroke program in China

Neuralstem, Inc. (NYSE Amex: CUR) announced it has signed a Memorandum of Understanding with BaYi Brain Hospital in Beijing, China.

21 Apr 2011

Blocking abnormal movement of mutated human FUS gene also blocks ALS process

In the first animal model of Amyotrophic Lateral Sclerosis (ALS), developed by Dr. Udai Pandey, Assistant Professor of Genetics at LSU Health Sciences Center New Orleans, Dr. Pandey's lab has found in fruit flies that blocking the abnormal movement of a protein made by a mutated gene called FUS also blocks the disease process.

20 Apr 2011

Neuralstem to present HSSC Phase I trial data in amyotrophic lateral sclerosis at AAN meeting

Neuralstem, Inc. announced that the Phase I safety trial of its human spinal cord stem cells in amyotrophic lateral sclerosis is the subject of three presentations at the American Academy of Neurology Annual Meeting, April 9-16th, in Honolulu, HI.

7 Apr 2011

BrainStorm provides review of recent accomplishments for shareholders, investors

BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell technologies and therapeutics, today provided a review of recent accomplishments for shareholders and investors.

25 Mar 2011

Study identifies potential therapeutic target for neurodegenerative disorders

Cell biologists pondering the death of neurons - brain cells - said today that by eliminating one ingredient from the cellular machinery, they prolonged the life of neurons stressed by a pesticide chemical. The finding identifies a potential therapeutic target to slow changes that lead to neurodegenerative disorders such as Parkinson's and Alzheimer's diseases.

14 Mar 2011

hUCBs and MenSCs transplant may offer future therapeutic benefit for AD, stroke, ALS

Transplanting stem cells derived from umbilical cord blood cells and menstrual blood cells may offer future therapeutic benefit for those suffering from stroke, Alzheimer's disease, and amyotrophic lateral sclerosis, says a team of neuroscience researchers from the University of South Florida's Department of Neurosurgery and Brain Repair and collaborators from three private-sector research groups, Saneron CCEL Therapeutics, Inc., Tampa, FL, Cryo-Cell International, Inc., Oldsmar, FL, and Cryopraxis, Cell Praxis, BioRio, Rio de Janeiro, Brazil.

8 Mar 2011

Scientists detail role of TDP-43 in ALS pathology

Amyotrophic lateral sclerosis, known as ALS or more popularly, Lou Gehrig's disease, is a notorious neurodegenerative condition characterized by the progressive deterioration of brain and spinal cord neurons, resulting in the gradual but catastrophic loss of muscle control and ultimately, death.

5 Mar 2011

Viruses that are natural part of human genome may retrovirus culprit

A retrovirus that inserted itself into the human genome thousands of years ago may be responsible for some cases of the neurodegenerative disease amyotrophic lateral sclerosis (ALS), also known as Lou Gherig’s disease. The finding, made by Johns Hopkins scientists, may eventually give researchers a new way to attack this universally fatal condition.

2 Mar 2011

BrainStorm raises $3.6 million through private placement financing

BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell technologies and therapeutics, announced today that it has entered into securities purchase agreements with certain institutional and other investors in connection with a private placement financing in reliance upon Regulation S. BrainStorm received gross proceeds of approximately $3.6 million resulting from the sale of shares at a purchase price of $0.28 per share at the closing of the transaction.

28 Feb 2011

Aestus commences ATx08-001 phase 2 trial to evaluate efficacy of novel pain therapeutic

Aestus Therapeutics, Inc., announced today that it has initiated screening of patients for a clinical trial to evaluate the efficacy of its novel pain therapeutic, ATx08-001. This placebo-controlled, two-dose level study will test the efficacy of ATx08-001 in reducing the pain following an outbreak of shingles.

23 Feb 2011

FDA grants BrainStorm's NurOwn orphan drug designation for treatment of ALS

BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell technologies and therapeutics, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the Company's NurOwn™ autologous adult stem cell product candidate for the treatment of amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig's Disease.

14 Feb 2011

Neuralstem updates progress of ongoing clinical trial of spinal cord stem cells in treatment of ALS

Neuralstem, Inc. updated the progress of its ongoing Phase I human clinical trial of the company's spinal cord stem cells in the treatment of ALS (amyotrophic lateral sclerosis, or Lou Gehrig's disease) at Emory University in Atlanta, Georgia.

11 Feb 2011

FDA grants Neuralstem orphan drug designation for treatment of ALS with spinal cord stem cells

Neuralstem, Inc. announced that the U.S. Food and Drug Administration's Office of Orphan Products Development has granted it orphan drug designation for the treatment of Amyotrophic Lateral Sclerosis (ALS) with its human spinal cord derived neural stem cells (NSI-566RSC), currently in a Phase I safety study to evaluate the safety of the product and the surgical route of administration in a wide range of ALS patients.

10 Feb 2011

Two new studies report GOT may improve health outcomes of stroke patients

Much of the devastation of stroke and head trauma is due to damage caused the overproduction of a substance in the brain called glutamate. Preventing this damage has been impossible, until now, as many drugs don't cross the so-called blood-brain barrier, and those that do often don't work as intended. But a method originally devised at the Weizmann Institute of Science may, in the future, offer a way to avert such glutamate-induced harm.

9 Feb 2011

Amyotrophic Lateral Sclerosis (ALS) News and Research

Proteostasis acquires Harvard University's two novel protein target licenses

Major breakthrough in understanding of amyotrophic lateral sclerosis

Rxi secures SBIR grants to develop novel RNAi therapeutics for ALS

Researchers report game-changing advance in stem cell science

U-M receives Taubman Institute's $100 million gift for innovative medical science

Biogen Idec first quarter revenues increase 9% to $1.2 billion

Neuralstem signs MoU with BaYi Brain Hospital for ischemic stroke program in China

Blocking abnormal movement of mutated human FUS gene also blocks ALS process

Neuralstem to present HSSC Phase I trial data in amyotrophic lateral sclerosis at AAN meeting

BrainStorm provides review of recent accomplishments for shareholders, investors

Study identifies potential therapeutic target for neurodegenerative disorders

hUCBs and MenSCs transplant may offer future therapeutic benefit for AD, stroke, ALS

Scientists detail role of TDP-43 in ALS pathology

Viruses that are natural part of human genome may retrovirus culprit

BrainStorm raises $3.6 million through private placement financing

Aestus commences ATx08-001 phase 2 trial to evaluate efficacy of novel pain therapeutic

FDA grants BrainStorm's NurOwn orphan drug designation for treatment of ALS

Neuralstem updates progress of ongoing clinical trial of spinal cord stem cells in treatment of ALS

FDA grants Neuralstem orphan drug designation for treatment of ALS with spinal cord stem cells

Two new studies report GOT may improve health outcomes of stroke patients

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News